{"title": "Novavax Covid Booster Wins US Emergency Authorization", "author": "Fiona Rutherford", "url": "https://www.bloomberg.com/news/articles/2022-10-19/novavax-s-covid-19-booster-shot-wins-us-emergency-authorization", "hostname": "bloomberg.com", "description": null, "sitename": "Bloomberg", "date": "2022-10-19", "cleaned_text": "Prognosis Novavax Covid Booster Wins US Emergency Authorization - Pre-clinical data suggest dose helps ward off Covid variants - CEO says booster may win over those skeptical of mRNA shots [Novavax Inc.](https://www.bloomberg.com/quote/NVAX:US)'s Covid-19 booster for people 18 and older was authorized by US regulators, offering another option to those seeking protection ahead of a potential wave of cases this winter. The booster dose can be administered six months after completion of primary vaccination with an authorized or approved Covid-19 vaccine. Novavax's booster shot is also available in adults for whom an messenger RNA bivalent shot is not accessible or clinically appropriate. Have a confidential tip for our reporters? Get in Touch Before it's here, it's on the Bloomberg Terminal LEARN MORE Up Next Novavax Covid Booster Wins US Emergency Authorization "}